Promising breast cancer drug trial stopped early – what happened?
NCT ID NCT06162351
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tested a new drug called PLX038 in 14 people with advanced triple-negative breast cancer that had already been treated. The goal was to see if the drug could shrink tumors. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 75248 Cedex, France
-
Institut Curie
Saint-Cloud, 92210, France
Conditions
Explore the condition pages connected to this study.